Skip to main content

Athersys needs to raise capital to survive, CEO says

In June, Athersys embarked on a financial and operational restructuring to lower its cost and conserve cash while commercialization its adult stem-cell therapy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.